Wide Ranks

JSPR

Jasper Therapeutics, Inc.

23.24

Top Statistics
Market Cap 348 M Forward PE -5.22 Revenue Growth 0.00 %
Current Ratio 7.61 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.84 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 92 M Total Cash Per Share 6.17 Total Debt 2 M
Total Debt To Equity 2.47 Current Ratio 7.61 Book Value Per Share 5.58
All Measures
Short Ratio 610.00 % Message Board Id finmb_647336542 Shares Short Prior Month 1 M
Return On Equity -0.7146 City Redwood City Uuid d05c20fd-d0e0-395b-bf20-ba58829de0f6
Previous Close 22.63 First Trade Date Epoch Utc 1 B Book Value 5.58
Beta 2.20 Total Debt 2 M Volume 183783
Price To Book 4.17 Last Split Date 1 B Fifty Two Week Low 4.00
Total Cash Per Share 6.17 Shares Short Previous Month Date 1 B Target Median Price 69.00
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 69.50
Net Income To Common -63529000 Short Percent Of Float 0.1309 Implied Shares Outstanding 15 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 218360
Average Volume10days 218360 Total Cash 92 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0498 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 22.63 Target Low Price 43.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 20.27 Open 22.66
Free Cashflow -36906376 State CA Dividend Yield 0.00 %
Return On Assets -0.4092 Time Zone Short Name EST Trailing Eps -4.75
Day Low 22.66 Address1 2200 Bridge Pkwy Shares Outstanding 15 M
Price Hint 2 Target High Price 90.00 Website https://www.jaspertherapeutics.com/
52 Week Change 2.78 Average Volume 280506 Forward Eps -4.52
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 744.50 %
Last Split Factor 1:10 Regular Market Day High 23.85 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 2.47 Fifty Two Week High 31.01
Day High 23.85 Shares Short 1 M Regular Market Open 22.66
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.1292 Operating Cashflow -57947000 Currency USD
Time Zone Full Name America/New_York Market Cap 348 M Is_nasdaq_100 False
Zip 94065 Quote Type EQUITY Industry Biotechnology
Long Name Jasper Therapeutics, Inc. Regular Market Day Low 22.66 Held Percent Institutions 1.00
Current Price 23.24 Address2 Suite 102 Enterprise To Ebitda -3.84
Financial Currency USD Current Ratio 7.61 Industry Disp Biotechnology
Number Of Analyst Opinions 8 Country United States Float Shares 9 M
Two Hundred Day Average 21.89 Enterprise Value 258 M Forward PE -5.22
Regular Market Volume 183783 Ebitda -67268000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.

The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation.

In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency.

Jasper Therapeutics, Inc. is headquartered in Redwood City, California.